Johnson & Johnson $JNJ Shares Bought by Stratos Investment Management LLC

Stratos Investment Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 19,948 shares of the company’s stock after acquiring an additional 1,094 shares during the quarter. Stratos Investment Management LLC’s holdings in Johnson & Johnson were worth $3,047,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in JNJ. Nuveen LLC acquired a new position in Johnson & Johnson during the 1st quarter worth $1,369,188,000. Bank of New York Mellon Corp boosted its stake in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. boosted its stake in Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in Johnson & Johnson during the 2nd quarter valued at $401,420,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. UBS Group increased their price target on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday. Raymond James Financial increased their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Finally, Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.59.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $193.27 on Friday. The firm has a market cap of $465.45 billion, a PE ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40. The business has a fifty day simple moving average of $180.49 and a 200-day simple moving average of $164.86. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.